Home › Targets › JAK2 V617F

JAK2 V617F (2 companies · 3 programs)

Companies with an active program directed at JAK2 V617F.

Prelude Therapeutics Inc PRLD

PRT12396 — Polycythemia Vera Phase 1
PRT12396 — Myelofibrosis Phase 1

Cogent Biosciences, Inc. COGT

CGT1145 Preclinical